ANI PHARMACEUTICALS, INC Long-term Line of Credit
ANI PHARMACEUTICALS, INC (ANIP) had Long-term Line of Credit of $25.00 million as of 2017-09-30, per its 10-Q filed 2017-11-02.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:LineOfCredit · last filed 2017-11-02
- 2017-09-30: Long-term Line of Credit $25.00M.
- 2017-06-30: Long-term Line of Credit $30.00M.
- 2017-03-31: Long-term Line of Credit $30.00M.
| Period end | Long-term Line of Credit |
|---|---|
| 2017-09-30 | $25.00M 10-Q · filed 2017-11-02 |
| 2017-06-30 | $30.00M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $30.00M 10-Q · filed 2017-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |